Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5198723, 8 pages
https://doi.org/10.1155/2017/5198723
Review Article

Cell-Based Models for Development of Antiatherosclerotic Therapies

1Institute of General Pathology and Pathophysiology, Moscow, Russia
2INSERM UMR_S 1166-ICAN Faculté de Médecine Pitié-Salpêtrière, Paris, France
3Institute for Atherosclerosis Research, Skolkovo Innovation Center, Moscow, Russia

Correspondence should be addressed to Emile R. Zakiev; rf.mresni@veikaz.lime

Received 9 October 2016; Accepted 11 January 2017; Published 14 February 2017

Academic Editor: Fabrizio Montecucco

Copyright © 2017 Emile R. Zakiev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Simmons, K. Steffen, and S. Sanders, “Medical therapy for peripheral arterial disease,” Current Opinion in Cardiology, vol. 27, no. 6, pp. 592–597, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. G. S. Berenson, S. R. Srinivasan, W. Bao, W. P. Newman III, R. E. Tracy, and W. A. Wattigney, “Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults,” New England Journal of Medicine, vol. 338, no. 23, pp. 1650–1656, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. H. C. McGill Jr., E. E. Herderick, C. A. McMahan et al., “Atherosclerosis in youth,” Minerva Pediatrica, vol. 54, no. 5, pp. 437–447, 2002. View at Google Scholar · View at Scopus
  4. E. M. Tuzcu, S. R. Kapadia, E. Tutar et al., “High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults evidence from intravascular ultrasound,” Circulation, vol. 103, no. 22, pp. 2705–2710, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. K. M. Anderson, P. W. F. Wilson, P. M. Odell, and W. B. Kannel, “An updated coronary risk profile. A statement for health professionals,” Circulation, vol. 83, no. 1, pp. 356–362, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. F. G. R. Fowkes, D. Rudan, I. Rudan et al., “Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis,” The Lancet, vol. 382, no. 9901, pp. 1329–1340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. V. Tertov, A. N. Orekhov, V. S. Repin, and V. N. Smirnov, “Dibutyryl cyclic AMP decreases proliferative activity and the cholesteryl ester content in cultured cells of atherosclerotic human aorta,” Biochemical and Biophysical Research Communications, vol. 109, no. 4, pp. 1228–1233, 1982. View at Publisher · View at Google Scholar · View at Scopus
  8. A. N. Orekhov, I. A. Sobenin, N. V. Korneev et al., “Anti-atherosclerotic therapy based on botanicals,” Recent Patents on Cardiovascular Drug Discovery, vol. 8, no. 1, pp. 56–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. N. Orekhov, “Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention,” Current Pharmaceutical Design, vol. 19, no. 33, pp. 5909–5928, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Babelova, D. G. Sedding, and R. P. Brandes, “Anti-atherosclerotic mechanisms of statin therapy,” Current Opinion in Pharmacology, vol. 13, no. 2, pp. 260–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-H. Yu, N. Jiang, P.-B. Yao, X.-L. Zheng, F. S. Cayabyab, and C.-K. Tang, “NPC1, intracellular cholesterol trafficking and atherosclerosis,” Clinica Chimica Acta, vol. 429, pp. 69–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Profumo, B. Buttari, L. Saso, and R. Riganò, “Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin,” Current Topics in Medicinal Chemistry, vol. 14, no. 22, pp. 2542–2551, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. E. A. Stein and F. J. Raal, “New therapies for reducing low-density lipoprotein cholesterol,” Endocrinology and Metabolism Clinics of North America, vol. 43, no. 4, pp. 1007–1033, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Mendel, N. Yacov, D. Harats, and E. Breitbart, “Therapies targeting innate immunity for fighting inflammation in atherosclerosis,” Current Pharmaceutical Design, vol. 21, no. 9, pp. 1185–1195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. L. Catapano, M. Farnier, J. M. Foody et al., “Combination therapy in dyslipidemia: where are we now?” Atherosclerosis, vol. 237, no. 1, pp. 319–335, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Artom, F. Montecucco, F. Dallegri, and A. Pende, “Carotid atherosclerotic plaque stenosis: the stabilizing role of statins,” European Journal of Clinical Investigation, vol. 44, no. 11, pp. 1122–1134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J. G. Robinson, “Starting primary prevention earlier with statins,” American Journal of Cardiology, vol. 114, no. 9, pp. 1437–1442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. J. Chee, H. H. V. Chan, and N. C. Tan, “Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review,” Singapore Medical Journal, vol. 55, no. 8, pp. 416–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Klose, U. Laufs, W. März, and E. Windler, “Familial hypercholesterolemia: developments in diagnosis and treatment,” Deutsches Arzteblatt International, vol. 111, no. 31-32, pp. 523–529, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Wilkinson, L. J. Laffin, and M. H. Davidson, “Overcoming toxicity and side-effects of lipid-lowering therapies,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 28, no. 3, pp. 439–452, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. D. M. Diamond and U. Ravnskov, “How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease,” Expert Review of Clinical Pharmacology, vol. 8, no. 2, pp. 201–210, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Riccioni, “The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review,” Current Medicinal Chemistry, vol. 16, no. 8, pp. 988–996, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Velasco, E. Rojas, and V. B. Pirela, “Approach to a successful selection of antihypertensive drugs for the patient with atherosclerosis,” American Journal of Therapeutics, vol. 20, no. 4, pp. 442–447, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. H. Hernández, M. J. Armas-Hernández, M. Velasco, Z. H. Israili, and M. C. Armas-Padilla, “Calcium antagonists and atherosclerosis protection in hypertension,” American Journal of Therapeutics, vol. 10, no. 6, pp. 409–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Kojima, K. Miyauchi, T. Yokoyama et al., “Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J),” Circulation Journal, vol. 75, no. 5, pp. 1071–1079, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Lim, M. J. Quon, and K. K. Koh, “Modulation of adiponectin as a potential therapeutic strategy,” Atherosclerosis, vol. 233, no. 2, pp. 721–728, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Simon, J. Gariépy, D. Moyse, and J. Levenson, “Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes,” Circulation, vol. 103, no. 24, pp. 2949–2954, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. N. Orekhov, V. V. Tertov, K. A. Khashimov, S. S. Kudryashov, and V. N. Smirnov, “Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells,” The American Journal of Cardiology, vol. 59, no. 5, pp. 495–496, 1987. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. Akopov, A. N. Orekhov, V. V. Tertov, K. A. Khashimov, E. S. Gabrielyan, and V. N. Smirnov, “Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta The effect of calcium antagonists,” Atherosclerosis, vol. 72, no. 2-3, pp. 245–248, 1988. View at Publisher · View at Google Scholar · View at Scopus
  30. A. N. Orekhov, V. V. Tertov, Kh. A. Khashimov, S. A. Kudryashov, and V. N. Smirnov, “Antiatherosclerotic effects of verapamil in primary culture of human aortic intimal cells,” Journal of Hypertension, vol. 4, pp. S153–S155, 1986. View at Google Scholar
  31. H. Ikeda, J. Minamikawa, Y. Nakamura et al., “Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study),” Diabetes Research and Clinical Practice, vol. 83, no. 1, pp. 50–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. W. F. Terpstra, J. F. May, A. J. Smit, P. A. De Graeff, B. Meyboom-De Jong, and H. J. G. M. Crijns, “Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial),” Journal of Hypertension, vol. 22, no. 7, pp. 1309–1316, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Heidarzadeh, B. Asadi, M. Saadatnia, A. Ghorbani, and F. Fatehi, “The effect of low-dose combined oral contraceptive pills on brachial artery endothelial function and common carotid artery intima-media thickness,” Journal of Stroke and Cerebrovascular Diseases, vol. 23, no. 4, pp. 675–680, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. E. F. Wolff, Y. He, D. M. Black et al., “Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS),” Fertility and Sterility, vol. 99, no. 5, pp. 1385–1391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Al-Waili, K. Salom, A. Al-Ghamdi, M. J. Ansari, A. Al-Waili, and T. Al-Waili, “Honey and cardiovascular risk factors, in normal individuals and in patients with diabetes mellitus or dyslipidemia,” Journal of Medicinal Food, vol. 16, no. 12, pp. 1063–1078, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Ried, C. Toben, and P. Fakler, “Effect of garlic on serum lipids: an updated meta-analysis,” Nutrition Reviews, vol. 71, no. 5, pp. 282–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. A. L. Hopkins, M. G. Lamm, J. L. Funk, and C. Ritenbaugh, “Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies,” Fitoterapia, vol. 85, no. 1, pp. 84–94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. K. Rai, P. Debetto, and F. Dabbeni Sala, “Molecular regulation of cholesterol metabolism: HDL-based intervention through drugs and diet,” Indian Journal of Experimental Biology, vol. 51, no. 11, pp. 885–894, 2013. View at Google Scholar · View at Scopus
  39. A. N. Orekhov, “Direct anti-atherosclerotic and anti-atherogenic effects of garlic,” European Journal of Clinical Research A, vol. 3, pp. 1–12, 1992. View at Google Scholar
  40. V. P. Karagodin, I. A. Sobenin, and A. N. Orekhov, “Antiatherosclerotic and cardioprotective effects of time-released garlic powder pills,” Current Pharmaceutical Design, vol. 22, no. 2, pp. 196–213, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Gorchakova, I. Suprun, I. Sobenin, and A. Orekhov, “Combined anti-inflammatory and anti-atherogenic activity of natural drug inflaminat—a perspective for long-term atherosclerosis prevention and treatment,” Atherosclerosis Supplements, vol. 8, no. 1, article 224, 2007. View at Publisher · View at Google Scholar
  42. T. Gorchakova, V. Myasoedova, I. Sobenin, and A. Orekhov, “Abstract: P387 atherosclerosis prevention with the anti-inflammatory dietary supplement Inflaminat,” Atherosclerosis Supplements, vol. 10, article no. 387, 2009. View at Google Scholar
  43. N. A. Nikitina, I. A. Sobenin, V. A. Myasoedova et al., “Antiatherogenic effect of grape flavonoids in an ex vivo model,” Bulletin of Experimental Biology and Medicine, vol. 141, no. 6, pp. 712–715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Sobenin, N. Nikitina, V. Myasoedova, V. Korenmaya, E. Khalilov, and A. Orekhov, “4P-1202 Antiatherogenic properties of isoflavones from phytoesrogen-rich botanicals,” Atherosclerosis Supplements, vol. 4, no. 2, p. 339, 2003. View at Publisher · View at Google Scholar
  45. J. R. Crouse III, R. P. Byington, M. G. Bond et al., “Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II),” The American Journal of Cardiology, vol. 75, no. 7, pp. 455–459, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. J. T. Salonen and R. Salonen, “Ultrasound B-mode imaging in observational studies of atherosclerotic progression,” Circulation, vol. 87, no. 3, pp. II56–II65, 1993. View at Google Scholar · View at Scopus
  47. T. J. Smilde, S. Van Wissen, H. Wollersheim, M. D. Trip, J. J. P. Kastelein, and A. F. H. Stalenhoef, “Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial,” Lancet, vol. 357, no. 9256, pp. 577–581, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Pitt, R. P. Byington, C. D. Furberg et al., “Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events,” Circulation, vol. 102, no. 13, pp. 1503–1510, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. H. N. Hodis, “Reversibility of atherosclerosis-evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study,” Journal of Cardiovascular Pharmacology, vol. 25, supplement 4, pp. S25–S31, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. D. H. Blankenhorn, R. H. Selzer, D. W. Crawford et al., “Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound,” Circulation, vol. 88, no. 1, pp. 20–28, 1993. View at Publisher · View at Google Scholar · View at Scopus
  51. D. H. Blankenhorn, S. P. Azen, D. M. Kramsch et al., “Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS),” Annals of Internal Medicine, vol. 119, no. 10, pp. 969–976, 1993. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Zanchetti, E. Agabiti Rosei, C. Dal Palù, G. Leonetti, B. Magnani, and A. Pessina, “The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness,” Journal of Hypertension, vol. 16, no. 11, pp. 1667–1676, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. V. B. Gencel, M. M. Benjamin, S. N. Bahou, and R. A. Khalil, “Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease,” Mini-Reviews in Medicinal Chemistry, vol. 12, no. 2, pp. 149–174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Myasoedova and I. Sobenin, “Background, rationale and design of clinical study of the effect of isoflavonoid-rich botanicals on natural history of atherosclerosis in women,” Atherosclerosis Supplements, vol. 9, no. 1, p. 171, 2008. View at Publisher · View at Google Scholar
  55. A. Oesterle, U. Laufs, and J. K. Liao, “Pleiotropic Effects of Statins on the Cardiovascular System,” Circulation Research, vol. 120, no. 1, pp. 229–243, 2017. View at Publisher · View at Google Scholar